The impact of open IP platforms on IP-strategy norms in life sciences Online publication date: Sun, 17-Jun-2012
by Tobias Thornblad; Thomas Hedner
International Journal of Technology Intelligence and Planning (IJTIP), Vol. 8, No. 1, 2012
Abstract: In the biomedical field multiple stakeholders may collaboratively develop, package and build transactions around technology. This is often referred to as open innovation, open biotechnology or open source R&D. Intellectual Property (IP) and IP rights play important roles in collaborative platforms but little research has previously assessed the impact that such platforms exert on corporate IP-strategies. A case study was therefore conducted of the Innovative Medicines Initiative (IMI), CAMBIA Biological Open Source (BiOS) and the Medicines for Malaria Venture (MMV). Our results impact managerial decision-makers at pharmaceutical, biotech and agriscience companies intending to implement corporate open innovation and IP strategies.
Online publication date: Sun, 17-Jun-2012
If you are not a subscriber and you just want to read the full contents of this article, buy online access here.Complimentary Subscribers, Editors or Members of the Editorial Board of the International Journal of Technology Intelligence and Planning (IJTIP):
Login with your Inderscience username and password:
Want to subscribe?
A subscription gives you complete access to all articles in the current issue, as well as to all articles in the previous three years (where applicable). See our Orders page to subscribe.
If you still need assistance, please email firstname.lastname@example.org